Montero-Vilchez, T.; Cuenca-Barrales, C.; Rodriguez-Tejero, A.; Martinez-Lopez, A.; Arias-Santiago, S.; Molina-Leyva, A.
Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. J. Clin. Med. 2022, 11, 1007.
https://doi.org/10.3390/jcm11041007
AMA Style
Montero-Vilchez T, Cuenca-Barrales C, Rodriguez-Tejero A, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A.
Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. Journal of Clinical Medicine. 2022; 11(4):1007.
https://doi.org/10.3390/jcm11041007
Chicago/Turabian Style
Montero-Vilchez, Trinidad, Carlos Cuenca-Barrales, Andrea Rodriguez-Tejero, Antonio Martinez-Lopez, Salvador Arias-Santiago, and Alejandro Molina-Leyva.
2022. "Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa" Journal of Clinical Medicine 11, no. 4: 1007.
https://doi.org/10.3390/jcm11041007
APA Style
Montero-Vilchez, T., Cuenca-Barrales, C., Rodriguez-Tejero, A., Martinez-Lopez, A., Arias-Santiago, S., & Molina-Leyva, A.
(2022). Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. Journal of Clinical Medicine, 11(4), 1007.
https://doi.org/10.3390/jcm11041007
